With the rise of multidrug resistance, Pseudomonas aeruginosa infections require alternative therapeutics. The injectisome (iT3SS) and flagellar (fT3SS) type III secretion systems are 2 virulence factors associated with poor clinical outcomes. iT3SS translocates toxins, rod, needle, or regulator proteins, and flagellin into the host cell cytoplasm and causes cytotoxicity and NLRC4-dependent inflammasome activation, which induces interleukin 1β (IL-1β) release and reduces interleukin 17 (IL-17) production and bacterial clearance. fT3SS ensures bacterial motility, attachment to the host cells, and triggers inflammation. INP1855 is an iT3SS inhibitor identified by in vitro screening, using Yersinia pseudotuberculosis. Using a mouse model of P. aeruginosa pulmonary infection, we show that INP1855 improves survival after infection with an iT3SS-positive strain, reduces bacterial pathogenicity and dissemination and IL-1β secretion, and increases IL-17 secretion. INP1855 also modified the cytokine balance in mice infected with an iT3SS-negative, fT3SS-positive strain. In vitro, INP1855 impaired iT3SS and fT3SS functionality, as evidenced by a reduction in secretory activity and flagellar motility and an increase in adenosine triphosphate levels. As a result, INP1855 decreased cytotoxicity mediated by toxins and by inflammasome activation induced by both laboratory strains and clinical isolates. We conclude that INP1855 acts by dual inhibition of iT3SS and fT3SS and represents a promising therapeutic approach.
Multidrug resistance in Pseudomonas aeruginosa is spreading worldwide, encouraging research on alternative therapeutic strategies [1] . In this context, targeting virulence is appealing because disarming bacteria rather than killing them may reduce their pathogenicity while avoiding emergence of resistance. Type III secretion systems (T3SSs) represent a specialized class of secretion machines dedicated to assembly of injectisomes and flagella [2] . P. aeruginosa has 2 T3SSs, namely iT3SS (translocating effectors in the host cells) and fT3SS (ensuring bacterial motility).
The iT3SS is associated with poor clinical outcome in acute infections [3] . iT3SS is made of a syringe-like machine injecting bacterial toxins (ExoU or ExoS, ExoT, and ExoY) from the bacterial cytosol directly into the host cell by the concerted action of a needle complex and a translocon (proteins PopB, PopD, and PcrV). ExoU is a phospholipase A2 causing rapid cell death by altering membrane integrity, while ExoS and ExoT cause disruption of actin filaments (thereby preventing phagocytosis) and cytotoxicity (ExoS mainly). ExoY also contributes to actin cytoskeleton disorganization [4] . Importantly, iT3SS translocates other bacterial proteins, such as FliC (the monomeric subunit of flagellum), into the host cell cytosol [5, 6] , which activate the cytosolic sensor NLRC4 (NLR family, CARD domain containing 4) inflammasome, resulting in pyroptosis [7] . Although the hypothesis is controversial [7] , NLRC4 inflammasome activation and the subsequent release of interleukin 1β (IL-1β) and interleukin 18 is thought to contribute to lung injury and impaired P. aeruginosa clearance by reducing interleukin 17 and antimicrobial peptides production [8] [9] [10] . Last, iT3SS regulates its own expression (Supplementary Figure 1) [11] . Under inducing conditions, iT3SS secretes the negative regulator ExsE, liberating the anti-antiactivator ExsC and allowing it to displace the negative regulator ExsD from its binding to the transcriptional activator ExsA, allowing thereby iT3SS gene transcription.
fT3SS consists of a membrane-anchored basal body forming the flagellum, required for bacterial motility, adhesion to host cells, bacterial dissemination, or initiation of inflammatory response [1, 12] . iT3SS and fT3SS share several general features. Their assembly depends on a T3SS located in the inner membrane and occurs following a similar process. Proteins directly involved in the secretion activity of iT3SS and the export activity of fT3SS share a high degree of similarity [13] .
Inhibiting T3SS is thus an attractive therapeutic strategy [14] . However, no low-molecular-weight inhibitor has been evaluated so far against P. aeruginosa in vivo. Hydroxyquinolines inhibit iT3SS gene expression in Yersinia pseudotuberculosis and Chlamydia trachomatis [15] but have not been studied against P. aeruginosa. Among them, INP1855 ( Figure 1A ) was the most effective inhibitor of iT3SS gene expression in Y. pseudotuberculosis. The present study aims to evaluate INP1855 efficacy in a murine model of pseudomonal acute pulmonary infection and to assess how it modulates pathogen-host cell interactions.
MATERIALS AND METHODS

T3SS Inhibitor
INP1855 was provided by Creative Antibiotics Sweden (Umeå, Sweden). Stock solutions were prepared in dimethyl sulfoxide (DMSO; 10-16 mM) and stored at room temperature in the dark for <1 month.
In Vitro Studies
Bacteria, Cells, and Culture Conditions
Strains and plasmids are shown in Table 1 . Twenty clinical isolates were collected from acute infections [16] . All strains were grown in lysogeny broth (LB) at 37°C with constant shaking (130 rpm). Growth curves were determined starting from overnight cultures resuspended in LB supplemented with INP1855 or its vehicle and adjusted to an OD 620nm of 0.1. The OD 620nm was followed over time while maintaining the culture at 37°C with aeration and constant shaking (300 rpm). Myelomonocytic THP-1 cells (ATCC TIB-202) [17] and alveolar epithelial A549 cells (ATCC CCL-185) [18] were grown in Roswell Park Memorial Institute 1640 medium and DMEM respectively, supplemented with 10% fetal calf serum. Adherent A549 cells were seeded in culture plates 2 days prior experiments.
Real-time Polymerase Chain Reaction (PCR)
Gene expression was measured as previously described [16] , using the primers shown in Supplementary Table 1 and starting from cultures at an OD 620nm of 0.8 in LB plus 5 mM EGTA and 20 mM MgCl 2 .
Western Blots
Bacteria were cultivated as for real-time PCR experiments. Proteins were collected [16] after separation of bacteria by centrifugation ( for 15 minutes at 20 800 g). Supernatants were concentrated by centrifugation (for 10 minutes at 4000 g) through Amicon Ultra 4 centrifugal filters. Proteins were measured using the Bradford assay, and Western blots were performed as described elsewhere [16] , using the following antibodies: anti-ExoS (dilution, 1:5000; Agrisera, Vännäs, Sweden), anti-GSK (dilution, 1:1000; Cell Signaling Technology, Danvers, MA), anti-FliC (dilution, 1:100; InvivoGen, Toulouse, France), anti-DsbA1 [19] (dilution, 1:30), and appropriate horseradish peroxidase-coupled secondary antibodies. Blots were revealed by chemiluminescence. Band intensity was quantified using Image J software, version 1.47V (available at: http:// imagej.nih.gov/ij/).
Motility Assay
These experiments were performed as previously described [20] , starting from overnight cultures resuspended in LB with DMSO or INP1855 and grown from an OD 620nm of 0.1-0.8 with aeration and constant shaking (300 rpm).
ATP Assay
Bacteria were cultivated as for real-time PCR experiments. The ATP level was measured in lysates by bioluminescence, using the ATP Determination Kit (Molecular probes, Eugene, OR).
Cytotoxicity Assay
Cytotoxicity was determined by measuring the release of the cytoplasmic enzyme lactate dehydrogenase (LDH) in culture medium [16] .
P. aeruginosa Internalization in THP-1 Cells
Overnight cultures were pretreated for 3 hours with INP1855 or DMSO, resuspended in Roswell Park Memorial Institute 1640 medium with 10% human serum in the presence of INP1855 or DMSO, and incubated for 1 hour at 37°C to allow opsonization [21] . Bacteria were added to monocytes in the presence of INP1855 or DMSO. Infected cells were incubated at 37°C for 2 hours to allow phagocytosis, washed in phosphate-buffered saline, and then exposed to 200 mg/L tobramycin for 1 hour to kill extracellular bacteria. Cells were washed in phosphatebuffered saline and lysed in sterile water, and aliquots were plated on agar for CFU determination after incubation at 37°C. Results were normalized per milligram of cell protein.
Inflammasome Activation and Flagellin Translocation in the Host Cells
Cytokine Assay
Except when stated otherwise, THP-1 cells were preincubated for 4 hours with 100 ng/mL lipopolysaccharide (LPS; to stimulate cytokine production) and 10 mg/L brefeldin A (to prevent interleukin 6 and tumor necrosis factor α (TNF-α) secretion [22] ). Cytokine levels were measured by enzyme-linked immunosorbent assay (ELISA) [16] in supernatants of cells incubated for 5 hours with bacterial strains, INP1855, DMSO, nigericin, or combinations thereof.
Caspase-1 Activation and IL-1β Maturation THP-1 monocytes were preincubated for 4 hours with 100 ng/mL LPS; incubated for 5 hours, as described for cytokine assays; and used for the study of caspase-1 activation or of IL-1β maturation. IL-1β was detected in cell lysates (pro-form) and extracellular medium (mature form). Western blots were performed as described . Plain lines denote infected mice, and dotted lines denote uninfected mice. Statistical analysis was performed by the log-rank test, comparing untreated and treated mice (n = 8 or 6 for each group of mice; 2 independent experiments were performed and showed similar results). E, Histological analysis of lungs from mice infected and treated as described in panel D (hematoxylin-eosin staining; original magnification ×100).
above, using the following primary antibodies: caspase-1 p10 (1:100; SantaCruz Biotechnology, Santa Cruz, CA), IL-1β (1:1000; R&D Systems), and anti-actin (Sigma-Aldrich) polyclonal antibody.
Flagellin Translocation
THP-1 cells were preincubated for 1 hour with cytochalasin D (to prevent phagocytosis) and incubated for 5 hours with bacteria in the presence of INP1855 or DMSO together with cytochalasin D. Cells were then centrifuged, washed, and incubated for 1 hour with tobramycin. FliC was detected by Western blot in cell lysates.
Animal Studies
C57BL/6J mice had free access to a chow diet in a temperaturecontrolled specified-pathogen-free environment, as determined by the Federation for Laboratory Animal Science Associations recommendations, with a half-day light cycle. Animals were lightly anesthetized with inhaled sevoflurane and infected by intranasal instillation of bacterial suspensions. INP1855 was administered either intranasally at the time of infection or intraperitoneally 4 hours later. Lung injury, bacterial burden and dissemination, cell counts, and cytokines in bronchoalveolar lavage (BAL) were determined using described procedures [8] . Histological analysis of lungs was performed using standard procedures and hematoxylin-eosin staining [23] in a blinded fashion.
Ethics Statement
Animal experiments were performed in an accredited establishment (N8 B59-108; Faculté de médecine de Lille, France) according to the governmental guidelines N886/609/CEE. They were approved by the local animal experimentation ethical committee of the région Nord-Pas-de-Calais (N8 CEEA 03/ 2004R). Animal care and procedures were in accordance with the French Guide for the Care and Use of Laboratory Animals and with the guidelines of the European Union.
Curve Fittings and Statistical Analyses
Curve fittings were performed with GraphPad Prism (version 6.05) and statistical analyses with GraphPad InStat (version 3.10) from GraphPad Software (San Diego, California).
RESULTS
Activity of INP1855 in Murine Acute Lung Infection
To demonstrate a protective effect of INP1855, mice were infected intranasally by CHA (iT3SS-and fT3SS-positive strain) and received at the same time a single dose of INP1855 (or its vehicle) by the same route. While survival was only 38% after 48 hours in CHA-infected mice receiving the vehicle, it reached 88% for INP1855-treated mice ( Figure 1B) . Survival was 50% in mice infected with a translocation-defective strain (CHAΔpopBD) and slightly (but not significantly) prolonged for those that received INP1855 ( Figure 1C ). To demonstrate a therapeutic effect, INP1855 was administered intraperitoneally to CHA-infected animals 4 hours after the infection. A dosedependent protective effect was observed ( Figure 1D ). INP1855 was innocuous for uninfected animals by both administration routes. Histological examination of lungs revealed a thickening of alveolar septa, an infiltration by inflammatory cells, and a loss of parenchyma organization in infected mice, which were reduced by INP1855 treatment ( Figure 1E ). To examine the INP1855 effect on bacterial dissemination and host response, mice were infected with sublethal inocula generating approximately 2%-3% injury in the lungs. In CHA-infected mice, INP1855 significantly reduced lung injury, bacterial burden, and dissemination to the spleen ( Figure 2A) ; it did not change the total number of cells in BAL but decreased neutrophil and increased macrophage recruitment ( Figure 2B ). INP1855 also significantly decreased IL-1β and increased IL-17 levels in BAL without affecting TNF-α ( Figure 2C ; see Supplementary Figure 2 for additional inflammatory markers). In CHAΔ-popBD-infected mice, INP1855 significantly reduced dissemination to the spleen, neutrophils counts, and IL-1β and TNF-α levels in BAL and increased IL-17 levels. These parameters were less affected in mice infected with CHAΔpopBDΔfliC and were not modified by INP1855 (Supplementary Figure 3) .
INP1855 Innocuity
Nonspecific toxic effects were ruled out by demonstrating that INP1855 did not modify CHA growth rate at concentrations of ≤250 µM and did not induce LDH release from THP-1 monocytes and A549 epithelial cells at concentrations of ≤60µM and after 5 (THP-1 cells) or 7 (A549 cells) hours of incubation (see Supplementary Figure 4 , with justification of the incubation times).
Influence of INP1855 on Phagocytosis and Cytotoxicity
Because ExoS and ExoT inhibit bacterial internalization in eukaryotic cells [24, 25] , we examined the effect of INP1855 on phagocytosis. INP1855 improved CHA internalization without affecting that of a strain that lacks iT3SS expression (CHAΔexsA; Supplementary Figure 5A ). To evaluate the effect of INP1855 on CHA-induced cytotoxicity, we used THP-1 and A549 cells, which respond differently to infection by iT3SS-expressing strains [26] because A549 do not express NLRC4 [27] , which is involved in inflammasome activation [28] . As shown in Supplementary Figure 5B , INP1855 decreased CHA cytotoxicity in a concentration-dependent manner in both cell types, reaching 40%-45% inhibition at 60 µM. Using this fixed concentration, we evaluated the effect of INP1855 on the cytotoxicity of CHA, PA103, and selected mutants ( Figure 3 ). Wild-type CHA and PA103 and mutants with constitutive iT3SS expression (PA103ΔexsD and PA103ΔexsE) were cytotoxic; this toxicity was significantly reduced by INP1855. Strains deleted for the translocation apparatus (CHAΔpopBD, PA103ΔpcrV) or the ExsA regulator (ΔexsA) caused minimal LDH release, which was unchanged by INP1855. Strains deleted for toxins (CHAΔSTY and PA103ΔUT) were selectively toxic for THP-1 cells (via inflammasome activation [16] ), and this toxicity was reduced by INP1855 as for parental strains.
Influence of INP1855 on Gene Transcription
The mRNA levels for genes encoding iT3SS toxins (exoS, exoU [PA103], and exoT [both strains]) or the translocation apparatus ( popB, popD, and pcrV) were measured in CHA, PA103, and its constitutive mutants (PA103ΔexsD and PA103ΔexsE; Figure 4A ). INP1855 reduced the expression of these genes in CHA or PA103 by 20%-50% (these results were confirmed using a bioluminescent reporter strain, which also allowed us to show that this inhibition was concentration dependent [Supplementary Figure 6] ). Of note, INP1855 was not a general inhibitor of transcription since it did not affect the expression of other genes, such as lasR and rhlR (quorum sensing regulators; determined in CHA [ Figure 4A] ). INP1855 did not change iT3SS gene expression in PA103ΔexsD (data not shown) and PA103ΔexsE, indicating that it does not directly act on iT3SS transcription but rather perturbs the ExsACDE regulatory cascade. Last, the effect of INP1855 on iT3SS gene transcription was not influenced by Phe-Arg-β-naphthylamide, a nonspecific efflux pump inhibitor, suggesting that INP1855 is not a substrate for efflux pumps (data not shown).
Influence of INP1855 on iT3SS Secretory Activity, Flagellar Motility, and Bacterial ATP Content
The effect of INP1855 was examined on the secretion of 3 proteins, namely ExoS, FliC, and ExsE, comparing their relative abundance in lysates from bacterial pellets and culture supernatants. With no anti-ExsE antibody available, we used a CHA strain transformed with the pUY44wt plasmid encoding ExsE coupled to a GSK tag [29] . INP1855 caused a concentrationdependent reduction in ExoS, FliC, and ExsE abundance in supernatants and a commensurate increase of their abundance in pellets ( Figure 4B ). Supernatants were not contaminated by nonsecreted proteins, since the inner membrane protein DsbA1 was detected in pellets only (Supplementary Figure 7) .
Assembly of the bacterial flagellum depends upon another T3SS (fT3SS) [13] . We therefore studied the effect of INP1855 on flagellar motility. INP1855 reduced swimming of CHA in a concentration-dependent manner ( Figure 4C) ; it also impaired swarming of CHA and CHAΔexsA (Supplementary Figure 8) . Of note, a strong correlation was observed between the capacity of INP1855 to inhibit iT3SS secretory activity and fT3SS-mediated motility (Supplementary Figure 9) . Collectively, these data suggest that INP1855 inhibits both iT3SS and fT3SS. Since both systems require an ATPase, we measured ATP levels in flagellated CHA and unflagellated PA103 and their exsA deletion mutants ( Figure 4D ). INP1855 significantly increased ATP content in CHA, PA103, and CHAΔexsA but not in PA103ΔexsA, which has neither iT3SS nor fT3SS. Because the ATPases of both T3SSs are highly homologous [13] , we wondered whether INP1855 could inhibit these enzymes. Because the purified T3SS ATPase from P. aeruginosa was not available, we used YscN, the homologous iT3SS ATPase from Y. pseudotuberculosis. INP1855 caused a time-and concentration-dependent inhibition of this enzyme (Supplementary Figure 10) . (5 × 10 7 CFU) and received a concomitant treatment with either 4.5 µg (10 nmol) INP1855 (black bars) dissolved in 1.67% dimethyl sulfoxide (DMSO) or 1.67% DMSO only (white bars) by the same route; mice were euthanized after 16 hours. Two independent experiments were performed and showed similar results. A, Lung injury index assessed by alveolar capillary barrier permeability, bacterial burden in the lungs after 24-hour culture, and bacterial dissemination assessed by spleen culture homogenates. Data are means ± SD (n = 5). B, Cell counts in bronchoalveolar lavage (BAL) fluid. Data are means ± SD (n = 5). C, Abundance of interleukin 1β (IL-1β), interleukin 17 (IL-17), and tumor necrosis factor α (TNF-α), measured by enzyme-linked immunosorbent assay in supernatants of BAL fluid. Data are means ± SD (n = 10). *P < .05, **P < .01, and ***P < .001, by the t test (when comparing untreated and treated mice) or 2-way analysis of variance with the Bonferroni post hoc test (when comparing cell types in BAL fluid). Abbreviation: UI, uninfected animals.
Influence of INP1855 on Inflammasome Activation in THP-1 Cells
The protective effect of INP1855 on cytotoxicity of CHAΔSTY and PA103ΔUT (expressing no toxins) for THP-1 cells (Figure 3) could result from an inhibition of inflammasome activation (Supplementary Figure 11) [8] . Flagellin translocation was therefore studied by Western blot in THP-1 cells incubated with CHA, CHAΔpopBD, or CHAΔfliC in the presence of INP1855 ( Figure 5A ). A strong signal was observed only for cells exposed to CHA, and its intensity was reduced by 45% by INP1855. We then examined the effect of INP1855 on caspase-1 activation and on release and maturation of IL-1β in the supernatant of THP-1 monocytes incubated with CHA and CHAΔSTY. Both strains induced caspase-1 activation ( Figure 5B ) and maturation and release of IL-1β ( Figure 5C ), and these effects were impaired by INP1855. IL-1β was also measured by ELISA in supernatants of cell cultures exposed to CHA, CHAΔSTY, CHAΔpopBD, and CHAΔexsA. TNF-α was studied as a control because its secretion depends on the nuclear factor-κB pathway [30] , rather than on inflammasome activation ( Figure 5D ). Nigericin was used in parallel as an inducer of NLRP3 inflammasome [31] to test for INP1855 specificity. Among the bacterial strains, only CHA and CHAΔSTY induced IL-1β release, which was inhibited by INP1855. Nigericin also caused caspase-1 activation (Supplementary Figure 12) and IL-1β release ( Figure 5D ), but these effects were not reverted by INP1855. All strains, irrespective of whether they expressed the iT3SS, and the combination of LPS and nigericin increased TNF-α release, but this effect was not prevented by INP1855 ( Figure 5D ). Thus, INP1855 seemed to protect cells from iT3SS-induced NLRC4 inflammasome activation. Results obtained for THP-1 cells incubated with PA103 and its mutants are presented in Supplementary Figure 13 .
Influence of INP1855 on Cytotoxicity of Clinical Isolates
We then examined the effects of INP1855 on LDH release (from THP-1 and A549 cells) and IL-1β release (from THP-1 Figure 4 . INP1855 decreases nonconstitutive iT3SS transcription, secretion of ExoS and ExsE, and motility in iT3SS-expressing strains, and increases adenosine triphosphate (ATP) content in iT3SS-or fT3SS-expressing strains. A, Influence of INP1855 on iT3SS gene transcription. Messenger RNA (mRNA) levels of T3SS toxin (exoS, exoU, and exoT), T3SS translocation apparatus ( popB, popD, and pcrV), or QS transcriptional activator (lasR and rhlR) genes as determined by real-time polymerase chain reaction. CHA, PA103, and PA103ΔexsE were grown from cultures at OD 620nm values of 0.1-0.8 with constant shaking in the presence of 0.6% dimethyl sulfoxide (DMSO; vehicle) or 60 µM of INP1855 in 0.6% DMSO in low calcium medium (lysogeny broth, EGTA 5 mM, and MgCl 2 20 mM) at 37°C to stimulate iT3SS expression and secretory activity. Results are expressed as relative messenger RNA (mRNA) expression levels when compared to controls (CHA and PA103 grown in the absence of INP1855). Dotted lines indicate the basal expression levels in CHA or PA103. Values represent the mean ± standard error of the mean of 2 experiments performed in duplicate. ***P < .001, **P < .01, and *P < .05, by 2-way analysis of variance (ANOVA) with the Bonferroni post hoc test, for comparison of values measured in control conditions or in the presence of INP1855. B, Effect of INP1855 on ExoS, FliC, and ExsE secretion. CHA and CHA expressing ExsE-GSK were grown from cultures at OD 620nm values of 0.1-0.8 with constant shaking in the presence of 0.6% DMSO (control) or increasing concentrations of INP1855 in 0.6% DMSO in low-calcium medium containing arabinose 0.4%, gentamicin 100 mg/L, and carbenicillin 300 mg/L for CHA transformed with the pUY44wt and pUCPexsC plasmids. ExoS and FliC were detected by Western blot after separation by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of 2.5 µg (supernatants) or 5 µg of (lysates) proteins, and ExsE-GSK was detected after separation by SDS-PAGE of 50 µg (supernatants and lysates) or of proteins, using an antibody recognizing both phosphorylated and unphosphorylated GSK tags (anti-GSK). Band intensity was quantified using Image J software (Supplementary Figure 7) . C, Effect of INP1855 on swimming motility. CHA was grown from cultures at OD 620nm values of 0.1-0.8 with constant shaking in the presence of 0.6% DMSO (vehicle) or of increasing concentrations of INP1855 in 0.6% DMSO, after which 3 µL of the cultures were placed in the center of 0.3% lysogeny broth plates and grown overnight at 37°C. The area covered by bacteria was evaluated using the Quantity one software (Biorad). Values are mean ± SD of triplicates or quadruplicates. (Figure 6 ) [16] . As previously observed [16] , cytotoxicity was higher for strains expressing ExoU than those expressing ExoS. In THP-1 monocytes, INP1855 reduced cytotoxicity induced by ExoU-positive strains by 30% without impairing IL-1β release (the signal detected in this case corresponds to pro-IL-1β released from dead cells and is therefore not associated with inflammasome activation [16] ). INP1855 also reduced cytotoxicity and IL-1β release by 65%-70% for strains expressing ExoS. In A549 epithelial cells, INP1855 reduced cytotoxicity by 18% and approximately 30% in strains expressing ExoU and ExoS, respectively.
cells) induced by clinical isolates collected from patients with acute infections
DISCUSSION
This work is the first to study and assess the in vivo and in vitro activity of a pharmacological T3SS inhibitor against P. aeruginosa. In vivo, INP1855 shows protective effects against 4 hallmarks of iT3SS-mediated damage (mortality, lung injury, bacterial burden, and bacterial dissemination) [8, 9] in mice infected by an iT3SS-positive strain. It also reduces inflammation in mice infected by an iT3SS-negative FliC-positive strain but not by a FliC-negative strain, suggesting that it may target both iT3SS and fT3SS. In vitro, INP1855 reduces iT3SS-dependent cytotoxicity mediated by toxins or by NLRC4 inflammasome activation. Thus, the use of INP1855 may represent a novel approach in antipseudomonal therapy.
Five pieces of evidence designate a core component of the iT3SS and fT3SS as a primary target of INP1855. First, INP1855 inhibits the secretion of iT3SS substrates (ExoS, FliC, and ExsE). Second, INP1855 impairs flagellar motility in both iT3SS-positive and iT3SS-negative strains, indicating an action unrelated to iT3SS inhibition. Third, INP1855 is equipotent to inhibit iT3SS secretory activity and fT3SS-mediated motility. Fourth, INP1855 increases ATP levels only in strains expressing iT3SS, fT3SS, or both systems. Fifth, INP1855 inhibits the ATPase activity of the homologous YscN enzyme from Y. pseudotuberculosis (57% and 47% identity with PscN and FliI, respectively [BLAST alignment]). Although inhibition of pseudomonal T3SS ATPases remains to be established, the fact that INP1855 inhibits the Y. pseudotuberculosis iT3SS [15] validates the use of YscN in our assays. Thus, these combined data suggest a possible specific mechanism of action for INP1855 and support the conclusion that INP1855 inhibits both the iT3SS and fT3SS by interacting with a common molecular target.
Translocation of ExsE is an initiating signal to induce iT3SS gene expression. Although INP1855 was originally identified as an inhibitor of iT3SS transcription, our data show that its effect on this process is probably indirect (resulting from impaired ExsE secretion [32] ), since INP1855 protects against PA103-ΔexsE cytotoxicity without affecting its gene expression. Another innovative observation is that INP1855 impairs caspase-1 activation and the subsequent IL-1β release induced by iT3SS-positive strains, 2 events related to NLRC4 inflammasome activation [5, [7] [8] [9] . Two experimental findings support inhibition of this cascade. First, INP1855 reverses the cytotoxicity of toxin-deleted mutants, which is strictly related to NLRC4 inflammasome activation [16] . Second, INP1855 inhibits caspase-1 activation and maturation of proIL-1β triggered by iT3SS-positive strains [16] but not by nigericin. This effect is consistent with a decreased delivery of the NLRC4 inflammasome activator flagellin. Moreover, the profile of cytokines in CHA-infected animals treated by INP1855 is similar to that described for NLRC4-deficient mice infected by CHA [8] . TNF-α is reduced in INP1855-treated mice infected by CHAΔpopBD, possibly reflecting an inhibition of TLR5 activation mediated by FliC. Likewise, the disbalance in immune cells observed in INP1855-treated animals (increase in macrophages/decrease in neutrophils) has been reported in IL-1β −/− mice infected by PA103ΔU [33] or in NLRC4 −/− mice infected with CHA [8] , suggesting that it could be a consequence of the impairment of IL-1β maturation and secretion. In short, we propose that INP1855 acts as an antivirulence compound by specifically impairing the functionality of both Strains were grouped according to the expression of ExoU toxin (T3SS+ ExoU+ vs T3SS+ ExoU-) or ExoS toxin (ExoS++ : level of expression higher than that detected in CHA; ExoS+: level of expression lower than that detected in CHA [16] ). Values are mean ± standard error of the mean of 3 independent experiments performed in quadruplicate (LDH) or duplicate (IL-1β). ***P < .001 and **P < .01, by 2-way analysis of variance with the Bonferroni post hoc test, for comparison of control conditions with INP1855. Abbreviation: NS, not significant. the iT3SS and the fT3SS ( presumably by inhibiting the ATPase activity of their basal core) while only indirectly impairing iT3SS gene expression. This effect leads to reduced motility and increased phagocytosis of bacteria and to decreased cytotoxicity and inflammasome activation in the host cells (Supplementary Figure 14) .
Compared with other antipseudomonal strategies [14] , INP1855 may offer several advantages. First, it protects from cytotoxicity induced not only by toxins but also by the injectisome itself and may, therefore, display a broader spectrum of activity than antitoxin agents [34, 35] . Second, in contrast to antibodies specifically directed against injectisome proteins [36] , INP1855 also inhibits flagellum-mediated toxicity, another determinant in pathogenicity [37, 38] (another drawback of antibodies is their unfavorable pharmacokinetics due to their proteic nature). Third, INP1855 is not a substrate for active efflux, which is a clear advantage over antibiotics [39] . Fourth, the changes in cytokine profile induced by INP1855 in mice are generally recognized as beneficial to the host. Although their findings are sometimes controversial [7, 23] , animal and clinical studies demonstrate that high levels of IL-1β impair Pseudomonas clearance [9, 10] . Conversely, IL-17 stimulates the production of antimicrobial peptides [8] .
Thus, pending for further investigations aimed at better characterizing the molecular targets of INP1855, examining its pharmacokinetic/pharmacodynamic profile, or evaluating its activity toward more-established infections, as well as in combination with antibiotics, this work could be considered as a first successful proof of concept that pharmacological inhibitors of T3SS may have beneficial effects on pseudomonal acute pulmonary infection by attenuating toxin effects and favorably modulating the host inflammatory response. In a biological context, studying the action of INP1855 also proved useful to better document the way P. aeruginosa interacts with its host.
Supplementary Data
Supplementary materials are available at http://jid.oxfordjournals.org. Consisting of data provided by the author to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the author, so questions or comments should be addressed to the author. CHA caused 25-30 % cytotoxicity and a massive release of IL-1β in wild-type and in trl5 -/-macrophages. Remarkably, CHA∆STY showed a similar profile despite the fact it did not express any toxin but still the translocation apparatus. On the contrary, both strains were unable to affect nlrc4 -/-or in caspase1 -/-macrophages. On the other side, CHA∆exsA and CHA∆popBD did not show any toxicity, whatever the cell type used, and did not cause any significant release of IL-1β, confirming the T3SS apparatus role in inflammasome activation. Thus, taken together, these data confirm that strains expressing a functional T3SS apparatus can induce IL-1β release and cytotoxicity that require the expression of NLRC4 and caspase-1.
